1. Home
  2. APM vs THAR Comparison

APM vs THAR Comparison

Compare APM & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APM
  • THAR
  • Stock Information
  • Founded
  • APM 2010
  • THAR 2017
  • Country
  • APM United Kingdom
  • THAR United States
  • Employees
  • APM N/A
  • THAR N/A
  • Industry
  • APM Biotechnology: Pharmaceutical Preparations
  • THAR Biotechnology: Pharmaceutical Preparations
  • Sector
  • APM Health Care
  • THAR Health Care
  • Exchange
  • APM Nasdaq
  • THAR Nasdaq
  • Market Cap
  • APM 18.9M
  • THAR 16.8M
  • IPO Year
  • APM 2018
  • THAR 2022
  • Fundamental
  • Price
  • APM N/A
  • THAR $3.03
  • Analyst Decision
  • APM
  • THAR Strong Buy
  • Analyst Count
  • APM 0
  • THAR 1
  • Target Price
  • APM N/A
  • THAR $17.00
  • AVG Volume (30 Days)
  • APM 434.9K
  • THAR 743.6K
  • Earning Date
  • APM 04-30-2025
  • THAR 11-06-2025
  • Dividend Yield
  • APM N/A
  • THAR N/A
  • EPS Growth
  • APM N/A
  • THAR N/A
  • EPS
  • APM N/A
  • THAR N/A
  • Revenue
  • APM N/A
  • THAR N/A
  • Revenue This Year
  • APM N/A
  • THAR N/A
  • Revenue Next Year
  • APM N/A
  • THAR N/A
  • P/E Ratio
  • APM N/A
  • THAR N/A
  • Revenue Growth
  • APM N/A
  • THAR N/A
  • 52 Week Low
  • APM $0.46
  • THAR $0.95
  • 52 Week High
  • APM $7.49
  • THAR $9.08
  • Technical
  • Relative Strength Index (RSI)
  • APM 62.63
  • THAR 49.12
  • Support Level
  • APM $1.74
  • THAR $2.90
  • Resistance Level
  • APM $2.50
  • THAR $3.18
  • Average True Range (ATR)
  • APM 0.17
  • THAR 0.33
  • MACD
  • APM 0.05
  • THAR -0.02
  • Stochastic Oscillator
  • APM 77.22
  • THAR 36.76

About APM Aptorum Group Limited

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

About THAR Tharimmune Inc.

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Share on Social Networks: